Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that John Librie has been promoted to Senior Vice President, Sales and Marketing. Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules® (tizanidine hydrochloride), as well as oversee all pre-commercial and commercial initiatives around the Company’s lead development compound, Fampridine-SR. Fampridine-SR is a sustained-release tablet being studied to evaluate its safety and efficacy in improving walking ability in people with multiple sclerosis (MS).